ICCC has delivered its sharpest monthly rally in years, climbing 30% to $8.44 over the past month, with an 8% gain just this week. The timing matters: the stock is moving into a May 15 earnings date while the borrow market is loosening and governance is being actively reshaped.
The most noteworthy development is corporate rather than technical. ImmuCell filed two new Form 3s on April 23 — Anthony DiMarco and Gilles Guillemette are both freshly registered insiders as of April 15 — alongside several Form 4s filed around the same date for existing board members. An April 15 news item described board appointments and governance changes explicitly framed around advancing an innovation strategy. That wave of insider registration, combined with a DEF 14A proxy filed April 24 for a June 11 shareholder meeting, points to a company in active transition at the governance level. The context is equally important: the most recent CEO on the insider register, Paul Te Boekhorst, bought nearly 10,000 shares across three consecutive days in early December at prices between $4.87 and $5.50, just as the stock was testing multi-year lows. That cluster of buying preceded the current move by roughly five months.
The lending market has materially relaxed alongside the price rally. Borrowing costs have almost halved since mid-March — cost to borrow was above 10% in early March and has since eased to 5.4%. Availability is running loosely: utilization has dropped from a 52-week peak of 4.54% in early April to just 1.68% today, the lowest of the past year by a clear margin. That means far more shares are available to borrow relative to what's currently being shorted. Short interest itself remains trivial at just 0.43% of the free float — down sharply from around 0.59% in mid-April — and days to cover is just one day per FINRA's most recent fortnightly print. There is no meaningful short pressure here.
The factor picture reflects the stock's positioning as a small, thinly followed name rather than a momentum trade. The ORTEX short score has drifted down every session this week, from 32.8 on April 17 to 30.2 today, consistent with covering rather than new short-building. The days-to-cover rank (76th percentile) and utilization rank (75th percentile) sit elevated relative to the universe, largely because even small absolute changes move the needle on a micro-cap. Valuation data available in the snapshot shows a negative P/E, consistent with a pre-profitability biotech still burning cash. Enterprise value is approximately $73 million — a number that frames just how small this company is and how sensitive the share price can be to low-volume moves.
Ownership is concentrated. Norman Pessin holds 11.6% of shares and Jonathan Rothschild 5.7%, with neither reporting any change in their most recent filings. SRK Capital holds another 5.6%. Combined, the top three holders control more than 22% of the company. That concentration amplifies both the effect of any news catalyst and the thinness of the float available to trade — it is part of why the stock can move 30% in a month on modest volume.
Former CEO Michael Brigham sold 24,052 shares at $6.07 on March 20, his only transaction in the dataset. At $146,000, the sale is modest in dollar terms but is the only negative signal in an otherwise constructive insider picture. The incoming leadership cluster, by contrast, was buying at significantly lower prices, suggesting the transition itself may be the catalyst the market is repricing.
The May 15 earnings call is the next concrete event to watch — the combination of new board members, governance changes, and a proxy meeting set for June 11 means it will be the first major public forum for a company that appears to be reintroducing itself to investors.
See the live data behind this article on ORTEX.
Open ICCC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
